POTENTIAL BENEFITS OF GLP-1 RECEPTOR AGONIST IN DIALYSIS PATIENTS WITH TYPE 2 DIABETES: THE NEED FOR COMPREHENSIVE PHARMACOKINETIC AND HEMODIALYSIS ANALYSES

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses

Abstract The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic Remote Start Control Module target with maximally tolerated metformin and sodium-glucose co-transporter-2 (S

read more